Decrease of CD68 and MMP-3 expression in synovium by treatment of adalimumab for rheumatoid arthritis

Area of Science:

• Rheumatology
• Immunohistochemistry
• Molecular Biology

Background:

• Rheumatoid arthritis (RA) is a chronic inflammatory disease.
• Adalimumab is a biologic therapy used for RA.
• Understanding treatment mechanisms is crucial for RA management.

Purpose of the Study:

• To investigate histological changes in synovial tissue of non-responder RA patients treated with adalimumab plus methotrexate (MTX).
• To compare synovial tissue markers between MTX monotherapy and adalimumab plus MTX therapy.

Main Methods:

• Histological assessment of synovial tissues from RA patients (n=10) using hematoxylin and eosin (H&E) staining.
• Immunohistochemical analysis of seven molecules: TNF-α, IL-6, MMP-3, CD20, CD68, VEGF, and RANKL.

Main Results:

• Adalimumab treatment showed increased vascular and cell proliferation in synovial tissue compared to controls.
• Significant decrease in matrix metalloproteinase-3 (MMP-3) and CD68 expression in the adalimumab group.
• No significant difference in TNF-α, IL-6, or CD20 expression between groups.

Conclusions:

• Adalimumab's efficacy may be linked to the inhibition of CD68 and MMP-3 in the synovium.
• Vascular and cell proliferation observed in adalimumab-treated RA patients.
• CD68 and MMP-3 are implicated in the mechanism of adalimumab's action in RA.